免疫检查点抑制剂在晚期或复发性子宫内膜癌中应用的研究进展

Advances in the role of immune checkpoint inhibitors in advanced or recurrent endometrial carcinoma

目前,对于晚期或复发性子宫内膜癌可选择的治疗方案有限,治疗方案以铂类药物化疗为主,尚缺乏统一疗效的最佳二线治疗方案可供选择。因此,对于晚期和复发性子宫内膜癌患者需要新的更有效的治疗方案。免疫检查点抑制剂在程序性死亡配体1阳性子宫内膜癌患者中显示出良好的安全性和抗肿瘤活性。本研究将对免疫检查点抑制剂在晚期或复发性子宫内膜癌中的作用进行综述。

At present,the treatment options for advanced or recurrent endometrial cancer are limited,and platinum-based chemotherapy is the main treatment options.There is still a lack of the best second-line treatment options with unifbnn efficacy.Therefore,new and more efifective treatment options are needed for patients with advanced and relapsing endometrial cancer.Immunocheckpoint inhibitors have shown good safety and antitumor activity in patients with programmed death ligand l(PD-Ll)positive endometrial cancer.This study reviews the role of immune checkpoint inhibitors in advanced or recurrent endometrial carcinoma.